Register for this webinar to learn about emerging technologies with SARS-CoV-2 testing. With your registration, you will have access to the recording on demand through November 30, 2021.
DESCRIPTION
How are we staying ahead of the coronavirus? As the world looks ahead, Drs. Luning and Wang will discuss the information that is or will be available to help the laboratory medicine and broader healthcare community that will help combat the unique challenges of SARS-CoV-2 spread and testing. Learn about novel solutions and emerging technologies in SARS-CoV-2 testing. As the testing techniques are improving, you will need to learn how to improve communications with the broader healthcare team to coordinate testing and ultimately patient care.
TARGET AUDIENCE
This activity is designed for lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), point-of-care coordinators, and other laboratory professionals overseeing and/or carrying out SARS-CoV-2 testing.
LEARNING OBJECTIVES
At the end of this activity, participants will be able to:
- Summarize emerging SARS-CoV-2 testing approaches and technologies.
- Discuss the benefits and limitations of emerging SARS-CoV-2 testing strategies that take healthcare system characteristics into consideration.
- Incorporate best practice recommendations to standardize communication across the healthcare team.
FACULTY
Eline T. Luning Prak, MD, PhD
Professor of Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA, USA
Ping Wang, PhD, DABCC, FAACC
Professor of Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA, USA
DISCLOSURES AND STATEMENT OF INDEPENDENCE
AACC is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Eline T. Luning Prak, MD, PhD
- Research/Grant Support: Janssen Research and Development, sponsored research grant to study antibody repertoires
- Consultant Fees: Enpicom, paid consultant; Roche Diagnostics, paid consultant, virtual COVID advisory board
- Salary: Janssen sponsored research grant
- Board/Committee Membership/Advisory Board: Member, SAB The Antibody Society; Member, SAB Enpicom; Member SAB American Autoimmune-Related Diseases Association
Ping Wang, PhD, DABCC, FAACC
- Intellectual Property/Royalty Income: Inventor of Microbubbling Digital Assay
The following reviewers reported no relevant financial relationship:
Nikolina Babic, PhD, DABCC, FAACC; Y. Victoria Zhang, PhD, MBA, DABCC, FAACC
CONTENT VALIDITY
All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR All scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
ACCREDITATION STATEMENT
This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID# 2048. This activity was planned in accordance with ACCENT® Standards and Policies.
SUCCESSFUL COMPLETION STATEMENT
Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].